CRSP Crispr Therapeutics Ag

$54.06 +1.84%

Healthcare · Biological Products, (No Diagnostic Substances)

Crispr Therapeutics Ag (CRSP) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $5.2 billion. Shares last traded at $54.06, 31.1% below their 52-week high. Over the past year the stock is up 26.3%. Net profit margin is -16569.8%, below the peer median of 6.3%. Revenue declined 90.6% year over year.

Market Cap

$5.2B

Shares Out

96.4M

EPS (TTM)

$-11.96

P/E Ratio

—

P/S Ratio

1485.61

P/B Ratio

2.87

Dividend / Share

—

Dividend Yield

—

52-Week High

$78.44

52-Week Low

$42.22

Volume

43,254

Avg Vol (3m)

70,771.857

Performance

+7.53%

+13.49%

+15.22%

-3.37%

YTD

+0.50%

+26.29%

Chart

Full chart →

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)

54.84

SMA (50)

$52.73

SMA (200)

$55.54

Price vs SMA50

+2.53%

Price vs SMA200

-2.65%

ATR (14)

$2.81

Financials

Revenue

$4M

Net Income

$-582M

Gross Margin

—

Operating Margin

-18933.6%

Net Margin

-16569.8%

Return on Equity

-32.1%

Return on Assets

-21.3%

Current Ratio

17.96

Debt / Equity

0.32

Revenue Growth (YoY)

-90.6%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

Period	EPS (diluted)	Reported
Q1 2026	$-1.28	2026-05-04
FY 2025	$-6.47	2026-02-12
Q3 2025	$-5.12	2025-11-10
Q2 2025	$-3.98	2025-08-04
Q1 2026	$-1.58	2026-05-04
FY 2025	$-4.34	2026-02-12

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

CRSP vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers

1485.61 / 5.21 med

+28397% premium

Net margin vs peers

-16569.8% / 6.3% med

below median

1–14 of 14


AMGN	Amgen	$182.1B	23.62	4.96	21.0%	-1.27%
GILD	Gilead Sciences	$153.5B	18.04	5.21	28.9%	-1.46%
RVMD	Revolution Medicines, Inc.	$34.6B	-30.62	—	—	+3.14%
BIIB	Biogen	$29.0B	22.44	2.93	13.1%	-1.15%
MRNA	Moderna	$25.4B	-8.99	—	—	+3.22%
NBIX	Neurocrine Biosciences Inc	$15.9B	33.24	5.56	16.7%	-0.48%
EXEL	Exelixis, Inc.	$13.1B	16.68	5.62	33.7%	-1.04%
KRYS	Krystal Biotech, Inc.	$10.2B	50.02	26.33	52.6%	+1.68%
TECH	Bio-Techne	$9.1B	123.61	7.44	6.0%	+5.36%
HALO	Halozyme Therapeutics, Inc.	$8.1B	25.67	5.82	22.7%	-0.03%
IBRX	Immunitybio, Inc.	$7.7B	-21.87	—	—	+5.01%
RGEN	Repligen Corp	$7.4B	152.27	10.08	6.6%	-1.20%
KYMR	Kymera Therapeutics, Inc.	$7.4B	23.88	—	—	+0.44%
PCVX	Vaxcyte, Inc.	$7.4B	-9688.00	—	—	+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.